Suppr超能文献

碳酸镧咀嚼片对血液透析患者血清磷水平的进一步降低作用

Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.

作者信息

Yamashita Tetsuri, Ogawa Tetsuya, Takahashi Masaki, Mitsuhashi Tetsuya, Shizuku Junichi, Takahashi Naoshi, Ohba Takashi, Miyajima Sayako, Kabaya Takashi, Otsuka Kuniaki, Nitta Kosaku

机构信息

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, Japan

出版信息

Ther Apher Dial. 2013 Apr;17 Suppl 1:54-9. doi: 10.1111/1744-9987.12036.

Abstract

Lanthanum carbonate (LC) is one of the relatively new phosphate binders. The general LC dosage form is a chewable pharmaceutical preparation. This investigation was targeted to subjects who do not chew LC chewable preparations adequately, for the purpose of studying the clinical efficacy of changing to pulverized prescriptions, such as changes in serum phosphorus levels (P levels). The study took place at Minamisenju Hospital in October 2011, with 41 subjects on maintenance hemodialysis. We pulverized all of the LC chewable medicines of the LC insufficient mastication group (non-chewing: NC group, n = 18) using a crusher, and changed them to pulverized prescriptions. The testing period was set at 10 weeks. In the NC group, there was a significant lowering of P levels from 5.86 ± 1.31 mg/dL before pulverization of the LC chewable preparation (week 0) to 5.38 ± 1.26 mg/dL after 2 weeks of administration of the pulverized medication (P = 0.0310), 5.20 ± 1.25 mg/dL after 4 weeks (P = 0.0077), and 5.12 ± 1.34 mg/dL after 6 weeks (P = 0.0167). P levels in other patients than NC group showed no significant change. In this study, the P levels in the NC group was lowered significantly by changing the LC chewable to the pulverized prescription, and the residual LC images on the abdominal X-rays disappeared to the point where they could barely be confirmed.

摘要

碳酸镧(LC)是一种相对较新的磷酸盐结合剂。碳酸镧的一般剂型是可咀嚼的药物制剂。本研究针对的是那些不能充分咀嚼碳酸镧咀嚼制剂的受试者,目的是研究改用粉状制剂的临床疗效,如血清磷水平(P水平)的变化。该研究于2011年10月在南千住医院进行,有41名维持性血液透析患者参与。我们使用粉碎机将碳酸镧咀嚼不足组(非咀嚼组:NC组,n = 18)的所有碳酸镧咀嚼药物粉碎,并将其改为粉状制剂。测试期设定为10周。在NC组中,碳酸镧咀嚼制剂粉碎前(第0周)的P水平为5.86±1.31mg/dL,在服用粉状药物2周后降至5.38±1.26mg/dL(P = 0.0310),4周后为5.20±1.25mg/dL(P = 0.0077),6周后为5.12±1.34mg/dL(P = 0.0167),P水平显著降低。NC组以外的其他患者的P水平没有显著变化。在本研究中,通过将碳酸镧咀嚼剂改为粉状制剂,NC组的P水平显著降低,腹部X线片上残留的碳酸镧影像消失至几乎无法确认的程度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验